Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Journal of Psychopharmacology

Volumn 22, Issue 6, 2008, Pages 621-632

  Griffiths, R R ^a   Richards, W A ^b   Johnson, M W ^a   McCann, U D ^a   Jesse, R ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c Council on Spiritual Practices ^*  (United States)

Author keywords

Entheogen; Hallucinogen; Humans; Mystical experience; Psilocybin; Psychedelic; Religion; Spiritual

Indexed keywords

LYSERGIDE; MESCALINE; METHYLPHENIDATE; N,N DIMETHYLTRYPTAMINE; PSILOCYBINE;

ADULT; AFFECT; ARTICLE; BEHAVIOR CHANGE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LIFE SATISFACTION; MALE; MOOD CHANGE; MYSTICISM; NORMAL HUMAN; PERSONALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RELIGION; WELLBEING;

ADMINISTRATION, ORAL; ADULT; AFFECT; FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; KNOWLEDGE; MALE; MIDDLE AGED; MYSTICISM; PERSONALITY; PSILOCYBINE; QUALITY OF LIFE; QUESTIONNAIRES; RELIGION; SPIRITUALITY; TIME FACTORS;

EID: 50249103939     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108094300     Document Type: Article

References (49)

1. Abraham, HD, Aldridge, AM, Gogia, P. (1996) The psychopharmacology of hallucinogens. Neuropsychopharmacology 14: 285-298.
2. Benson, PL, Donahue, MJ, Erickson, JA (1993) The Faith Maturity Scale: conceptualization, measurement, and empirical validation. Research in the Social Scientific Study of Religion, Vol 5. Greenwich, Connecticut: JAI Press Inc, pp. 1-26.
3. C'de Baca, J., Wilbourne, P. (2004) Quantum change: ten years later. J Clin Psychol 60: 531-541.
4. Carter, OL, Hasler, F., Pettigrew, JD, Wallis, GM, Liu, GB, Vollenweider, FX (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 195: 415-424.
5. Carter, OL, Pettigrew, JD, Hasler, F., Wallis, GM, Liu, GB, Hell, D., et al. (2005) Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 30: 1154-1162.
6. Chwelos, N., Blewett, DB, Smith, CM, Hoffer, A. (1959) Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol 20: 577-590.
7. Costa, PT, McCrae, RR (1992) Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) Professional Manual. Odessa, FL: Psychological Assessment Resources.
8. Dittrich, A. (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31 (Suppl. 2). 80-84.
9. Doblin, R. (1991) Pahnke's Good Friday experiment: a long-term follow-up and methodological critique. J Transpersonal Psychol 23: 1-28.
10. Forcehimes, AA (2004) De profundis: spiritual transformations in Alcoholics Anonymous. J Clin Psychol 60: 503-517.
11. Frisch, MB (1994) QOLI, Quality of Life Inventory: Manual and Treatment Guide for the Quality of Life Inventory. Minneapolis, MN: National Computer Systems Inc.
12. Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, HJ, Kovar, KA, Lindenblatt, H., et al. (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE). psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142: 41-50.
13. Griffiths, RR, Richards, WA, McCann, U., Jesse, R. (2006) Psilocybin can occasion mystical experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268-283.
14. Halpern, JH, Pope, HG (1999) Do hallucinogens cause residual neuro-psychological toxicity ? Drug Alcohol Depend 53: 247-256.
15. Hasler, F., Grimberg, U., Benz, MA, Huber, T., Vollenweider, FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 172: 145-156.
16. Hollister, LE (1961) Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130: 42-52.
17. Hood Jr, RW, Ghorbani, N., Watson, PJ, Ghramaleki, AF, Bing, MN, Davison, HK, Morris, RJ, Williamson, WP (2001) Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J Sci Study Relig 40: 691-705.
18. Hood Jr, RW, Williamson, WP (2000) An empirical test of the unity thesis; the structure of mystical descriptors in various faith samples. J Psychology Christ 19: 232-244.
19. Isbell, H. (1959) Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1: 29-38.
20. James, W. (1902, republished 1958) The Varieties of Religious Experience. New York, NY: Penguin Books.
21. Johnson, MW, Richards, WA, Griffiths, RR (in press) Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22.
22. Kurland, A., Savage, C., Pahnke, WN, Grof, S., Olsson, JE (1971) LSD in the treatment of alcoholics. Pharmacopsychiatry 4: 83-94.
23. Leclerc, G., Lefrançois, R., Dubé, M., Hébert, R., Gaulin, P. (1999) Criterion validity of a new measure of self-actualization. Psychol Rep 85: 1167-1176.
24. Leary, T., Litwin, GH, Metzner, R. (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137: 561-573.
25. Mangini, M. (1998) Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs 30: 381-418.
26. Malitz, S., Esecover, H., Wilkens, B., Hoch, PH (1960) Some observations on psilocybin, a new hallucinogen, in volunteer subjects. Compr Psychiatry 1: 8-17.
27. Metzner, R. (2004) Teonanacatl: Sacred Mushroom of Visions. El Verano, CA: Four Tree Press.
28. Metzner, R., Litwin, G., Weil, G. (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5: 3-39.
29. Miller, WR, C'de Baca, J. (2001) Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives. New York, NY: The Guilford Press.
30. Nichols, DE (2004) Hallucinogens. Pharmacol Ther 101: 131-181.
31. Pahnke, WN (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. PhD Thesis presented to the President and Fellows of Harvard University in Religion and Society.
32. Pahnke, WN (1967) LSD and religious experience. In: DeBold, RC, Leaf, RC (eds). LSD Man & Society. Middletown, CT: Wesleyan University Press, pp. 60-85.
33. Pahnke, WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5: 149-162.
34. Pahnke, WN, Kurland, AA, Goodman, LE, Richards, WA (1969) LSD-assisted psychotherapy with terminal cancer patients. In: Hicks, RE, Fink, PJ, (eds). Psychedelic Drugs: Proceedings of a Hahnemann Medical College and Hospital Symposium. New York, NY: Grune and Stratton, pp. 33-42.
35. Peterman, AH, Fitchett, G., Brady, MJ, Hernandez, L., Cella, D. (2002) Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy-Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med 24: 49-58.
36. Piedmont, RL (1999) Does spirituality represent the sixth factor of personality? Spiritual transcendence and the five-factor model. J Pers 67: 985-1013.
37. Piedmont, RL (2007) Cross-cultural generalizability of the spiritual transcendence scale to the Philippines: spirituality as a human universal. Ment Health Relig Culture 10: 89-107.
38. Richards, WA, Rhead, JC, DiLeo, FB, Yensen, R., Kurland, AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9: 1-10.
39. Rinkel, M., Atwell, CR, Dimascio, A., Brown, J. (1960) Experimental psychiatry. V. Psilocybine, a new psychotogenic drug. N Engl J Med 262: 295-297.
40. Rosenberg, DE, Isbell, H., Miner, EJ, Logan, CR (1964) The effect of N, N-Dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia 5: 217-227.
41. Savage, C., McCabe, OL (1973) Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Arch Gen Psychiatry 28: 808-814.
42. Spilka, B., Hood Jr, RW, Hunsberger, B., Gorsuch, R. (2003) The Psychology of Religion: An Empirical Approach, third ed. New York: The Guilford Press.
43. Stace, WT (1960) Mysticism and Philosophy. Philadelphia, PA: Lippincott.
44. Stamets, P. (1996) Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, CA: Ten Speed Press.
45. Strassman, RJ, Qualls, CR, Uhlenhuth, EH, Kellner, R. (1994) Dose-response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51: 98-108.
46. Vollenweider, FX, Vollenweider-Scherpenhuyzen, MFI, Babler, A., Vogel, H., Hell, D. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902.
47. Wasson, RG (1980) The Wondrous Mushroom: Mycolatry in Mesoamerica. New York, NY: McGraw-Hill Book Co.
48. Watson, D., Clark, LA (1994) (updated 1999) The PANAS-X manual for the positive and negative affect schedule-expanded form. Iowa City, Iowa: The University of Iowa.
49. Wolbach Jr, AB, Miner, EJ, Isbell, H. (1962) Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia 3: 219-223.